Mt. Sinai receives NIH grant for microscope that sees real-time cellular activity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Institutes of Health has awarded a $1.2 million grant to the Mount Sinai Microscopy Core for a state-of-the-art microscope with resolution capabilities that can show structures as small as viruses. The instrument will be used by research teams throughout Mount Sinai Health System.

The grant will fund the purchase of a Leica TCS SP8 STED 3X, a super-resolution microscope, the first at Mount Sinai Health System. This new microscope will allow researchers to perform fluorescence nanoscopy and the ability to see tiny cellular processes that have previously been impossible to see.

The microscope will enable researchers to learn about several cellular processes, by, for example, observing a virus infecting the body, or seeing the molecular changes that occur when a tumor progresses to metastasis. The microscope’s super-resolution abilities will allow researchers to make gains in the study of viral infection, neurodegenerative disease progression, developmental brain disorders, metastasis, glaucoma, stress, and depression.

The microscope is set for installation in mid-December and will be accessible to all researchers in various areas of medicine throughout the health system.

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login